Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

About this trial

The main purpose of this study is to explore the value of multimodal imaging information and models in predicting the prognosis of EGFR-positive non-small cell lung cancer patients undergoing targeted therapy, providing a basis for selecting suitable populations for precise tumor treatment and corresponding therapy. We retrospectively analyzed patient case data, extracted preoperative CT images, H\&E-stained whole-slide digital pathology images, and pre- or postoperative genetic testing reports to extract radiomic features of tumor and peritumoral regions. These features were combined with multidimensional pathological features and gene expression distribution characteristics to construct a multimodal radiopathogenomic model, offering more precise prognostic evaluation for lung cancer patients receiving targeted therapy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18-80 years, undergoing radical surgery for lung cancer (R0 resection);

Postoperative pathological stage IB-IIIA, pathology confirmed as adenocarcinoma;

EGFR gene testing positive, EGFR 19del/L858R mutation;

Receiving postoperative EGFR-TKI targeted adjuvant therapy;

Disqualifiers

Patients negative for EGFR;

Incomplete surgical resection (R1, R2);

Did not receive EGFR-TKI targeted therapy after surgery;

Recurrent or advanced stage patients;

Trial population

Retrospectively included data from 1000 patients diagnosed with stage IB-IIIA invasive lung adenocarcinoma with EGFR mutations who underwent radical surgery from January 2021 to December 2024.

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

  • Comprehensive analysis through laboratory tests, imaging techniques, and clinical data

    Diagnostic test

    Extract radiomics features of the tumor and peritumoral regions from preoperative CT images, H\&E-stained digital pathology whole-slide images, and genetic test reports, and integrate them with multidimensional pathological features and gene expression distribution characteristics to construct a radiopathogenomic multi-omics modality, providing more precise prognostic assessment for targeted therapy in lung cancer patients.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

DFS

The endpoint of this study was disease-free survival (DFS), defined as the time interval from surgery to the first recurrence or death,assessed up to 24 months。

Time frame
two years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: